Investment Thesis

. Conversely, successful product launches or earnings beats could reinforce bullish sentiment, justifying an increase in position size.

Competitive Moat

Abbott possesses a strong intangible asset moat bolstered by its reputable brand and regulatory approvals, allowing it to command premium pricing in competitive markets. The company benefits from scale economies, particularly in its diagnostics segment, which is critical given the capital-intensive nature of the industry. While Abbott faces threats from emerging biotech firms and established competitors like Siemens and Medtronic, its entrenched market position and continuous innovation significantly enhance the durability of its competitive advantage over the next 5-10 years.

Growth Engine

Abbott's future revenue growth will primarily stem from its diagnostics and medical devices segments, which are projected to capture a growing share of a total addressable market (TAM) valued at over $60 billion by 2028. The company’s expansion into emerging markets and investment in new product lines, such as continuous glucose monitoring systems, provide additional avenues for organic growth. Abbott is gaining market share in both diagnostics and diabetes care, capitalizing on the increasing demand for personalized medicine and chronic disease management.